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From five mice immunized with Escherichia coli K1 bacteria, we produced 12 immunoglobulin M hybridomas
secreting monoclonal antibodies (MAbs) that bind to Neisseria meningitidis group B (NMGB). The 12 MAbs
also bound the capsular polysaccharide (PS) of E. coli K1 [which, like NMGB, is a(2-8)-linked polysialic acid
(PSA)] and bound to EV36, a nonpathogenic E. coli K-12 strain producing a(2-8) PSA. Except for HmenB5,
which cross-reacted with N. meningitidis group C, none of the MAbs bound to N. meningitidis groups A, C, and
Y. Of the 12 MAbs, 6 were autoantibodies as defined by binding to CHP-134, a neuroblastoma cell line ex-
pressing short-chain a(2-8) PSA; five of these MAbs killed NMGB in the presence of rabbit complement, and
two also killed NMGB with human complement. The other six MAbs, however, were nonautoreactive; all killed
NMGB with rabbit complement, and five killed NMGB with human complement. To obtain peptide mimotopes
of NMGB PS, four of the nonautoreactive MAbs (HmenB2, HmenB3, HmenB13, and HmenB14) were used to
screen two types of phage libraries, one with a linear peptide of 7 amino acids and the other with a circular
peptide of 7 amino acids inserted between two linked cysteines. We obtained 86 phage clones that bound to the
screening MAb in the absence but not in the presence of E. coli K1 PSA in solution. The clones contained 31
linear and 4 circular mimotopes expressing unique sequences. These mimotopes nonrandomly expressed ami-
no acids and were different from previously described mimotopes for NMGB PS. The new mimotopes may be
useful in producing a vaccine(s) capable of eliciting anti-NMGB antibodies not reactive with neuronal tissue.
Neisseria meningitidis is the most common cause of bacterial
meningitis in the United States, and a meningococcal vaccine is
currently licensed in the United States. However, this vaccine
needs to be improved for various reasons. First, this vaccine
contains capsular polysaccharides (PS) from N. meningitidis
serogroups A, C, Y, and W135 but not serogroup B (11). The
lack of protection against N. meningitidis group B (NMGB) in
a meningococcal vaccine is a serious shortcoming, because
NMGB may account for 50% or more of all meningococcal
meningitis cases in Europe and North America (3, 29). Second,
this vaccine does not elicit antibodies in young children, who
account for about 50% of meningococcal meningitis cases (29).
Although conjugation of the meningococcal PS to protein car-
riers makes group A, C, and Y capsular PS immunogenic in
young children, group B PS-protein conjugate remains poorly
immunogenic (19).
There are several obstacles to generating a vaccine effective
against NMGB. One obstacle is that NMGB PS may elicit auto-
antibodies. Antibodies to NMGB PS can be generated after
natural infection (25) or after immunization with a chemically
modified NMGB PS (18) or Escherichia coli K92 PS (9), which
is a polymer of sialic acid (PSA) with alternating a(2-8) and
a(2-9) linkages. However, the antibodies were found to bind
frequently to both NMGB PS and neuronal tissue (15, 25).
This cross-reaction occurs because both express a linear a(2-8)
PSA. NMGB PS is a PSA with about 200 repeating units (12),
and neuronal tissue has the same but shorter (about 10 to 50
repeating units) PSA as a part of neuronal cell adhesion mo-
lecule (NCAM) (8). Although the notion is controversial, the
antibodies cross-reacting with the neuronal PSA are thought to
have the potential to cause neurological damage. Another ma-
jor obstacle is the absence of simple alternative NMGB vaccine
candidate antigens. For instance, outer membrane proteins have
been used as a vaccine, but this approach is limited because of
significant serologic heterogeneity among different strains of
NMGB (3).
Two new approaches for generating an NMGB vaccine have
been suggested. One approach is to find a new vaccine candi-
date molecule. This approach received a significant boost from
the sequencing of the entire genome of NMGB (26). Another
approach is to use peptides that mimic the bacterium-specific
epitope of NMGB PS as the vaccine. The feasibility of this ap-
proach has been demonstrated with the evaluation of peptide
mimics of meningococcus group C (33). This approach has now
become more amenable with the development of phage display
technology (10, 30), which can be used to identify peptide
mimotopes of PS (31). We now report the development of
monoclonal antibodies (MAbs) that bind and kill NMGB with-
out binding neuronal PSA and use of these MAbs to identify
peptide mimotopes of NMGB capsular PS.
MATERIALS AND METHODS
Antigens and bacteria. Various strains of bacteria used for this study are
summarized in Table 1. All E. coli strains were cultured in Luria-Bertani (LB)
broth or on LB agar plates. Neisseria strains were grown on chocolate agar plates
in a candle jar. To obtain a large number of Neisseria bacteria with minimal
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biohazard, many chocolate agar plates were plated with the bacteria and the
bacteria were then harvested from the plates after a 6-h incubation at 37°C. All
bacteria were aliquoted in Hanks’ balanced salt solution (HBSS) containing 20%
glycerol and stored at 270oC.
Enzyme-linked immunosorbent assay (ELISA). Ninety-six-well microtiter
plates (Nunc, Roskilde, Denmark) were coated with various antibody capture
agents as described below. The plates were then washed with 0.05% Tween 20 in
phosphate-buffered saline (PBST) and blocked with 2% skim milk in PBST.
Appropriately diluted samples were added to the plates and incubated for 1.5 h
at 37oC. After washing, alkaline phosphatase-labeled goat anti-mouse immuno-
globulin (Ig; Sigma) was added. After a 90-min incubation, p-nitrophenyl phos-
phate was added to the plates and optical densities of the plates were measured
at 405 nm.
For different purposes, the plates were coated with different agents. Some
were coated with NMGB (ATCC 13090) by adding 100 ml of PBS containing
heat-killed NMGB (optical density at 620 nm 5 0.09) to each well and incubating
the plates overnight at 37oC (1). NMGB was killed by incubating the frozen
aliquots of NMGB at 65°C for 1 h followed by washes with PBS (0.82% NaCl,
1.28% Na2HPO4, pH 7.2). Some plates were coated with highly purified E. coli
K1 PS (gift of R. Silver and W. Vann) by adding 100 ml of PBS containing E. coli
K1 PS (10 mg/ml) to each well and incubating the plates at 37°C overnight in a
humidified chamber. To determine the isotypes of antibodies, alkaline phos-
phatase-labeled rabbit anti-mouse isotype-specific antibodies (Zymed, South San
Francisco, Calif.) were used.
Production of MAbs. BALB/cByJ mice from Jackson Laboratory (Bar Harbor,
Maine) were intraperitoneally immunized with E. coli K1 four times, twice with
107 CFU, on days 0 and 4, and twice with 108 CFU, on days 7 and 10. Live
bacteria were used for fusions 1, 2, and 3, but heat-killed bacteria were used for
fusions 4 and 5. Spleens were harvested on day 13 for fusion with Sp2/0-Ag14
myeloma cells, as described previously (24). The resulting hybridoma superna-
tants were screened by a sandwich-type ELISA as described above using ELISA
plates coated with purified E. coli K1 PS in the first test and plates coated with
killed NMGB bacteria in the second test. Only the hybridomas producing anti-
bodies binding to both NMGB bacteria and E. coli K1 PS were cloned. Twelve
hybridoma clones, all immunoglobulin M k [IgM(k)], were produced from five
fusions.
To obtain purified MAbs, the tissue culture supernatant was concentrated
10-fold with ammonium sulfate, dialyzed in PBS, and fractionated by size-exclu-
sion column chromatography using Sephacryl S-300HR (Pharmacia, Uppsala,
Sweden).
Flow cytometry. Flow cytometry was used to test MAbs for binding to various
strains of the bacteria, listed in Table 3. The bacteria were killed by incubation
in 2% formaldehyde for 1 h, washed with HBSS, and suspended at 5 3 108
CFU/ml in HBSS containing 1% glycine in order to neutralize any remaining
formalin. Twenty microliters of killed bacteria (5 3 108 CFU/ml) and 50 ml of
MAb (5 mg/ml) were mixed in a well of a microtiter plate. An irrelevant IgM
MAb was used as a negative control. After 1 h of incubation, this mixture of
bacteria and MAbs was washed and suspended in 100 ml of fluorescein isothio-
cyanate-conjugated anti-mouse Ig (Sigma). After 1 h of incubation, the bacteria
were washed again and fixed by resuspension in 400 ml of PBS containing 0.5%
paraformaldehyde. Fluorescence, forward scatter, and side scatter of the bacteria
were measured with a flow cytometer (FACScaliber; Becton Dickinson, Moun-
tain View, Calif.).
To test MAbs for binding to the PSA portion of NCAM, CHP-134 cells (21)
were stained with MAb for flow cytometry as described below. Five hundred
microliters of CHP-134 cell suspension (106 cells/ml) was mixed with 50 ml of
MAb solution (10 mg/ml) in a test tube and incubated for 2 h on ice. After
washing, the cells were incubated with 100 ml of fluorescein isothiocyanate-
conjugated goat anti-mouse Ig for 1 h at room temperature (RT). After another
wash, the cells were resuspended in 400 ml of PBS containing 0.25% formalde-
hyde. Anti-CD56 (PharMingen, San Diego, Calif.), which is specific for NCAM,
and isotype-matched irrelevant mouse MAbs were used as positive and negative
controls, respectively. Fluorescence, forward scatter, and side scatter of the cells
were measured with a flow cytometer (FACScaliber).
Bactericidal assay. The bactericidal assay was performed in 96-well microtiter
plates (Corning Inc., Corning, N.Y.) with modifications of a previously described
procedure (27). Briefly, 30 ml of bacterial suspension containing 2,500 CFU, 50
ml of appropriately diluted antibiotic-free antibody, and 20 ml of baby rabbit
complement or agammaglobulinemic human serum were added to each well.
The concentration of complement was 2 to 20% depending on the susceptibility
of the bacteria to the complement, and an isotype-matched irrelevant MAb was
used as a negative control. Target bacterial strains are listed in Table 1. Two
different strains of NMGB (ATCC 13090 and H44/76) were used to avoid killing
by binding to antigens that were not capsular PS. After a 1-h incubation with
shaking, 10 ml of the reaction mixture was plated on a chocolate agar plate. CFU
were determined after an overnight incubation at 37°C in a candle jar. Each assay
was performed in triplicate, and the mean of the triplicate was used to calculate
the percentage of killing by the formula [(CFUno antibody 2 CFUsample)/
CFUno antibody] 3 100. This assay was repeated at least two times.
Histochemistry. The staining was performed with the brains obtained from 1-
to 2-week-old C57BL/6 mice. Five-micrometer-thick cryosections of the brain
were incubated with 1 to 2 mg of MAb/ml for 75 min at RT. The slide was washed
with PBS and incubated with biotin-conjugated goat anti-mouse IgM antibody
(Vector Laboratories, Burlingame, Calif.) for 30 min at RT. The slide was
washed again with PBS and incubated with streptavidin-peroxidase (Jackson
ImmunoResearch Laboratory, West Grove, Pa.) for 30 min. The slide was de-
veloped with a peroxidase substrate, 3-amino-9-ethylcarbazole, from Scy Tek
(Logan, Utah) and counterstained with Mayer’s hematoxylin stain (Poly Scien-
tific, Bayshore, N.Y.).
Production of phage clones expressing the mimotopes. Two phage libraries
from New England Biolabs Inc. (Beverly, Mass.) were used for our study. One
contained a linear peptide with 7 amino acids, and the other contained a circular
peptide with 7 amino acids between two cysteines. The two cysteines were joined
by a disulfide bond to form a circular peptide. The phage library was biopanned
with purified MAbs HmenB1, HmenB2, HmenB3, HmenB13, and HmenB14, as
described by the manufacturer of the library. Briefly, MAb-coated 60-mm-diam-
eter culture dishes (Nunc) were prepared by incubating the dish with 1.5 ml of 0.1
M NaHCO3 (pH 8.6) containing 100 mg of MAb/ml overnight at 4°C, washing
with 0.1% Tween 20–Tris-buffered saline (0.1% TBST; 50 mM Tris-Cl [pH 7.5],
150 mM NaCl), and blocking with 0.5% bovine serum albumin in 0.1 M
NaHCO3. Phage binding to the MAb was enriched by incubating the phage
library in the dish, gently washing away unbound phage, and removing the phage
bound to the dish by elution with 0.2 M glycine-HCl (pH 2.2) and rapidly
neutralizing the phage with 1 M Tris-Cl (pH 9.1). Bound phage was expanded
and subjected to additional cycles of enrichment as described above. After three
cycles of enrichment, bound phage was cloned. Individual clones of phage were
expanded for further studies.
Binding and competitive binding assays of phage on antibody-coated plates.
Ninety-six-well microtiter plates (Nunc) were coated with MAbs by adding 100 ml
of a carbonate buffer (pH 9.6) containing 10 mg of MAb/ml. After an overnight
TABLE 1. Bacterial strains used for characterization of MAbs
Species Group Strain Characteristic(s) Sourcea
N. meningitidis A S-4185 A:21 FDA
A A21 A: CDC
A M239 (F8238) A:P1.5,2 CDC
B ATCC 13090 B: ATCC
B H44/76 B:15:P1.7,16 FDA
C BB-305 C:2b:P1.2 FDA
Y S-1975 Y:2a FDA
Y WRAIR 6304 Y:2a:P1.5,2 FDA
E. coli RS218 O18,K1,H7 University of Rochester
EV36 K-12 expressing K1 PS University of Rochester
a FDA, Food and Drug Administration; CDC, Centers for Disease Control and Prevention; ATCC, American Type Culture Collection.
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incubation, the plates were washed and blocked with 2% skim milk in PBST.
Fourfold serial dilution of the solutions containing amplified phage (1 3 1011 to
10 3 1011 PFU/ml) was performed, and the serially diluted phage was added to
the plates. In some cases, to test for the specificity of phage binding to MAb, a
serial dilution of E. coli K1 PS (from 1,600 to 0.2 mg/ml) or heat-inactivated
NMGB (1.6 3 1010 to 2 3 105 cells/ml) was added to the well along with a fixed
number of phage (1010 PFU/ml). After a 1.5-h incubation at RT with gentle
agitation, the plates were washed and loaded with peroxidase-labeled antiphage
MAb (Pharmacia). One and one-half hours later, the plates were washed and
loaded with tetramethylbenzidine (Kirkegaard & Perry Laboratories, Gaithers-
burg, Md.). The color development was stopped, and the plates were read at
450 nm.
DNA sequencing of phage peptide motif. To determine the DNA sequence of
the peptide mimotope, phage clones were expanded by growing them in 1-ml
E. coli cultures for 4 to 5 h at 37°C. To recover the phage, the bacteria were
removed from the culture suspension by a brief centrifugation (10,000 3 g for
10 s), 500 ml of the culture supernatant was mixed with 200 ml of 20% polyeth-
ylene glycol–2.5 M NaCl solution, and the mixture was centrifuged (10,000 3 g)
for 10 min. The pellet containing the phage was resuspended with 100 ml of a
Tris-EDTA (TE) buffer with iodide (10 mM Tris-Cl [pH 8.0], 1 mM EDTA, 4 M
NaI) and 250 ml of absolute ethanol. The phage was then washed with 70%
ethanol, dried, and resuspended in 30 ml of TE buffer. Five microliters of the
phage suspension was subjected to dideoxy termination reactions using a DNA
sequencing kit (Perkin-Elmer, Norwalk, Conn.), 296 sequencing primer from
New England Biolabs, and AmpliTaq DNA polymerase FS. The sequence of the
mimotope was obtained by running the above reaction products through an
automated DNA sequencer from Applied Biosystems (Foster City, Calif.).
RESULTS
Characterization of antigens for the MAb. From five mice
immunized with E. coli K1 bacteria (strain RS218), we ob-
tained 12 hybridomas expressing IgM heavy and k light chain
isotypes. Consistent with their selection prior to cloning, these
hybridoma antibodies bound to the ELISA plates coated with
NMGB bacteria and purified E. coli K1 PS (data not shown).
The preparation of E. coli K1 PS was highly purified and was
not likely contaminated with other antigens (W. Vann, per-
sonal communication). In addition, the 12 hybridoma antibod-
ies bound to EV36 (Table 2), which is an E. coli K-12 strain
possessing the genes for K1 capsular PS production (32) and
expresses nonacetylated a(2-8) PSA just like NMGB (R. Sil-
ver, personal communication). These findings taken together
strongly suggest that all the MAbs bind to a(2-8) PSA and/or
to a structure invariably associated with the PS (e.g., the lipid
anchor of the capsular PS [4, 14]).
To test the binding specificities of the MAbs for NMGB
bacteria in solution, we examined their binding to N. meningi-
tidis bacteria of groups A, B, C, and Y by flow cytometry (Ta-
ble 2). All MAbs bound to group B meningococci except for
HmenB4. Although it bound to NMGB immobilized on
ELISA plates, it did not bind to NMGB in solution even at
a high (5- to 10-mg/liter) antibody concentration. The cause
of this discrepancy may be technical; the flow cytometric
assay may be less sensitive than the ELISA. One hybridoma
(HmenB5) bound to group C meningococci as well as to group
B meningococci (Table 2). Since group C capsular PS is a(2-9)
PSA and group B capsular PS is a(2-8) PSA, the cross-reactive
epitope for HmenB5 is likely a part of the two very similar
capsular PS and is not likely another bacterial molecule such as
outer membrane protein. The remaining 10 MAbs strongly bound
only to NMGB without binding to N. meningitidis groups A, C,
and Y. Thus, the 10 MAbs are specific for NMGB PS.
Autoreactivities of the MAbs. Since antibodies to NMGB PS
often cross-react with human a(2-8) PSA expressed in neural
tissue, cross-reactivity of our MAbs with human PSA was ini-
tially assessed with a human neuroblastoma cell line, CHP-134
(21). CHP-134 expresses NCAM decorated with a 50-mer of
PSA (21) and can serve as a source of human PSA antigen.
More than 90% of the CHP-134 cells used for our study ex-
pressed a marker of NCAM, CD56 (Fig. 1A), indicating that
our CHP-134 cells expressed NCAM. Indeed, HmenB1,
HmenB4, HmenB5, HmenB8, HmenB9, and HmenB10 had
weak or moderate binding to CHP-134 cells at approximate-
ly 10 mg/liter (Table 2 and Fig. 1B). However, HmenB2,
HmenB3, HmenB6, HmenB7, HmenB13, and HmenB14 did
not bind to CHP-134 cells detectably under the conditions used
here (Table 2 and Fig. 1B). For instance, HmenB2, HmenB3,
HmenB13, and HmenB14 did not bind even at a high concen-
tration (25 mg/liter). Thus, some of the MAbs are specific for
the bacterial PSA and do not cross-react with human PSA.
To further delineate the binding of the MAbs to the brain
tissue, we examined HmenB1, HmenB3, HmenB13, and
HmenB14 for binding to the frozen section of the brain of a
newborn mouse. HmenB1 stained scattered cells in the cere-
brum and the Purkinje cells of the cerebellum at 2.8 mg/liter
(Fig. 1D). In contrast, the other three MAbs (HmenB3,
HmenB13, and HmenB14) as well as an IgM MAb binding
pneumococcal capsular PS did not stain the brain at similar
antibody concentrations (Fig. 1C and data not shown). This
finding further supports the conclusion that HmenB3,
HmenB13, and HmenB14 are not reactive with a(2-8) PSA
produced by the animal neuronal tissues.
Characterization of bactericidal activity of the MAb. Anti-
bodies may bind to bacteria without promoting the bactericidal
activity of complement (15). Thus, the MAbs were tested at the
concentrations of 5 and 0.5 mg/liter for killing N. meningitidis
group A (M239), B (ATCC 13090 and H44/76), C (BB-305),
and Y (S-1975) bacteria in the presence of rabbit or human
complement. Similar results were obtained with both antibody
concentrations, and results obtained at 0.5 mg/liter are shown
TABLE 2. Binding characteristics of MAbs by flow cytometry
Fusion
no. MAb name
Binding to:
E. coli
EV36a
N. meningitidis
groupa CHP-
134b
A B C Y
1 HmenB1 1 2 111 2 2 1
2 HmenB2 1 2 111 2 2 2
2 HmenB3 1 2 111 2 2 2
2 HmenB4 11 2 2 2 2 6
2 HmenB5 11 2 111 111 2 1
2 HmenB6 1 2 111 2 2 2
2 HmenB7 1 2 111 2 2 2
3 HmenB8 1 2 111 2 2 6
3 HmenB9 11 2 111 2 2 1
3 HmenB10 1 2 111 2 2 6
4 HmenB13 ND 2 111 2 2 2
5 HmenB14 ND 2 111 2 2 2
Immune mouse serum 11 2 11 1 2 1
a Binding of the antibody to the bacteria was determined with flow cytometry.
2, 6, 1, 11, and 111, ,5, 5 to 10, 10 to 40, 40 to 70, and 70 to 100% of
bacteria, respectively, displayed fluorescence above threshold levels. Target bac-
teria were strains S-4185, ATCC 13090, BB-305, and S-1975 for N. meningitidis
groups A, B, C, and Y, respectively. ND, not done.
b Binding of antibodies to PSA was determined by indirect fluorescence flow
cytometry using CHP-134 cells, a PSA-expressing neuroblastoma cell line. 1, 6,
and 2, .30, 15 to 30, and ,15% of cells, respectively, were above the threshold.
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in Table 3. No MAbs killed N. meningitidis groups A, C, and Y
to any detectable degree even at a high (5-mg/liter) concen-
tration, except for HmenB5. HmenB5, which bound group C
meningococci very well, readily killed group C meningococci in
the presence of rabbit complement (Table 3).
HmenB1 did not kill any NMGB strain with either rabbit or
human complement. The remaining 11 MAbs killed more than
70% of two different strains of NMGB (strains ATCC 13090
and H44/76) in the presence of rabbit complement, but their
bactericidal efficiency was quite variable. For instance, 1 ng of
HmenB3 per ml killed 50% of NMGB (strain ATCC 13090),
but 150 ng of HmenB14 per ml and 30 ng of HmenB13 per ml
were required to do the same (Fig. 2). Bactericidal efficiencies
of HmenB2 and HmenB3 were very similar (data not shown).
With human complement, three MAbs (HmenB4, HmenB7,
and HmenB8) had undetectable killing activities and two
MAbs (HmenB6 and HmenB9) showed only weak bacteri-
cidal activity, but six MAbs (HmenB2, HmenB3, HmenB5,
HmenB10, HmenB13, and HmenB14) continued to kill
NMGB quite effectively (Table 3).
Selection of phage clones and analysis of peptide sequence
motif. The above data taken together strongly suggested that
six MAbs bind to a(2-8) PSA (and/or its associated structures)
from NMGB and can promote killing of the bacterium by com-
plement but do not bind the a(2-8) PSA from neural tissue.
We therefore chose four (HmenB2, HmenB3, HmenB13, and
HmenB14) of the six hybridomas as well as HmenB1 (a neg-
ative control) to isolate peptide mimotopes. After three rounds
of biopanning a phage library displaying random linear and
circular peptides, many phage clones binding to ELISA wells
coated with the five MAbs were identified. A randomly chos-
en irrelevant phage (Pha-CNTL) clone bound poorly to these
wells (Fig. 3).
Ninety-two randomly chosen phage clones were subjected to
additional binding studies in order to establish the specificity of
their binding. All the phage clones bound only to the wells
coated with the relevant antibody and did not bind to the
wells coated with unrelated antibodies. For instance, PhaB1L1
bound to HmenB1-coated ELISA wells but did not bind to
HmenB3-coated wells. PhaB3L1 bound to HmenB3-coated
wells but not to HmenB1-coated wells (Fig. 4B). The binding
specificity involved PSA since the binding of phage to each
MAb was decreased with an increasing amount of purified
capsular PS of E. coli K1 as the inhibitor (Fig. 4A) but not with
an irrelevant PS. The binding of phage to each MAb was also
inhibitable with heat-inactivated group B meningococci (data
not shown). These findings indicate that the chosen phage
clones specifically bind to the MAbs used for the biopanning.
FIG. 1. (A and B) The number of CHP-134 cells (y axis) versus cellular fluorescence (x axis). (A) CHP-134 cells were stained with anti-CD56
(green line) or no antibody (dotted line). (B) Cells were stained with 25 mg of HmenB1 (red line) or HmenB3 (green line) per ml or no antibody
(dotted line). (C and D) A cryosection of 10-day-old mouse brain (cerebellum) was stained with HmenB3 (C) and HmenB1 (D). Positive-staining
cells have a brick-red color. Approximate magnifications, 357 (C) and 3110 (D).
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The nucleotide sequence of the inserted DNA of all the
cloned phage was determined, and the DNA sequences were
translated into amino acid sequences (Table 4). A surprising
observation was that the phage clones obtained with HmenB2
and HmenB3 had identical peptide mimotope sequences (data
not shown). HmenB2 and HmenB3 were obtained from one
fusion, and they could share clonal ancestry (Table 2). To
exclude shared clonal ancestry, we determined the DNA se-
quences of the V regions of these two hybridomas and found
them to be identical (data not shown), confirming our suspi-
cion, and the sequence data obtained with the two hybridomas
were pooled (Table 4).
Many phage clones had identical peptide sequences. For
instance, six phage clones were chosen with HmenB1, and
five of the six clones expressed the sequence of PhaB1L1
(Table 4). Among the phage clones obtained with HmenB3,
the SHVPNAH (PhaB3L1) sequence was found in 62% (23
of 37) of the phage clones. Such shared peptide sequences
were observed for the phage clones obtained with HmenB13
and HmenB14 as well. VVSTGSH (PhaB13L1) was seen in
31.3% of phage clones obtained with HmenB13. MELQTRS
(PhaB14L1) and LPMKYQA (PhaB14L2) each were observed
in 22.7% of phage clones obtained with HmenB14.
When the sequences were not identical, the sequences were
often very similar, and the similarity could be used to identify
consensus peptide sequences. PhaB1L2 shared 4 of the 7 ami-
no acids with PhaB1L1. The shared amino acid sequences were
HQ and FV, two polar and two nonpolar groups, respectively.
Many phage clones obtained with HmenB3 differed by only 1
or 2 amino acids from each other, and their consensus peptide
sequence was S-H-V/A-P/H-X-A-F. The consensus sequence
had 2 polar amino acids, 1 nonpolar amino acid, 1 amino acid
of either type, 1 polar amino acid, and 2 nonpolar amino acids,
in that order. Similarity in the peptide sequences was observed
among the phage clones obtained with unrelated MAbs. Pep-
tide sequences of PhaB13L3 and PhaB14L2 are identical, al-
though HmenB13 and HmenB14 were obtained from different
fusions and their V regions had different nucleotide sequences
(unpublished data). The first 4 amino acids of PhaB13L12
(SHAPYTH) are the same as those of PhaB3L2 and PhaB3L5.
Interestingly, the peptide sequences of phage clones obtained
with HmenB1 were totally different from those obtained with
HmenB3, HmenB13, and HmenB14.
DISCUSSION
Due to the clinical importance of NMGB, the binding spec-
ificity of antibodies to its capsular PS has been studied exten-
sively. The antibodies have been found to differ in their abili-
ties to kill NMGB bacteria in the presence of complement, in
their binding to NMGB PS of various lengths, and in their
cross-reactivities to various antigens including neuronal cells.
For instance, Jennings and his colleagues found that N-pro-
pionyl derivatization of NMGB reduces the induction of anti-
bodies binding the host NCAM and described the binding
FIG. 2. Bactericidal activities (y axis) at different concentrations of
MAb (x axis). Individual curves show the bactericidal activities against
NMGB (ATCC 13090) by HmenB3 (squares), HmenB13 (circles), and
HmenB14 (triangles). All the curves showing the bactericidal activities
against N. meningitidis groups A (strain M239), C (strain BB-305), and
Y (strain S-1975) by the three MAbs are inside the shaded triangle.
TABLE 3. Bactericidal characteristics of MAbsa
MAb
Result for complement source with N. meningitidis serogroup (strain)
Rabbit Human
B (ATCC 13090)A (M239) B (ATCC 13090) B (H44/76) C (BB-305) Y (S-1975)
HmenB1 2 2 2 2 2 2
HmenB2 2 111 111 2 2 111
HmenB3 2 111 111 2 2 111
HmenB4 2 11 111 2 2 2
HmenB5 2 111 111 111 2 111
HmenB6 2 111 111 2 2 1
HmenB7 2 111 111 2 2 2
HmenB8 2 111 111 2 2 2
HmenB9 2 111 111 2 2 11
HmenB10 2 111 111 2 2 111
HmenB13 2 111 111 2 2 111
HmenB14 2 111 111 2 2 111
Irrelevant antibody 2 2 2 2 2 2
a Bacterial assays were performed in triplicate, and the means of triplicates were used for calculations. 2, 1, 11, and 111, killing levels of ,5, 10 to 40, 40 to 70,
and .70%, respectively. The percent killing was calculated as follows: % killing of bacteria 5 [(CFUcontrol 2 CFUMAb)/CFUcontrol] 3 100. The bactericidal assay was
performed at 0.5 mg of MAb per ml and was performed at least two times to determine the reproducibility of the results. Baby rabbit serum was used at the
concentration of 2% except for group B strain ATCC 13090. For ATCC 13090, 10 to 20% baby rabbit serum and human serum were used. Rabbit serum before or
after heat inactivation did not kill the bacteria to any significant degree.
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specificity diversity among the hybridomas specific for N-pro-
pionylated NMGB (27). A recent study by Granoff et al. (15)
showed that hybridomas obtained from mice immunized with
N-propionylated NMGB differ in complement-dependent kill-
ing of NMGB bacteria and binding to NMGB PS. Further-
more, they found that some MAbs are autoreactive since they
bind to NCAM expressed on the CHP-134 cell line.
Although our MAbs were obtained by immunizing mice with
E. coli K1, they largely reflected the antigen binding pattern
described above. We have also obtained several autoreactive
hybridomas. For instance, HmenB1 readily bound the CHP-
134 cells and the brain tissue. Even though it readily bound to
NMGB PS, it was not bactericidal against NMGB. Another
autoreactive antibody was found to display unusual binding
properties: in addition to binding NMGB, HmenB5 bound to
the PS of group C N. meningitidis and killed this bacterium.
This type of antibody specificity may be produced with E. coli
K92 immunization, but one MAb reported in the literature
with the identical binding property was produced with NMGB
immunization (20). Group C PS in the meningococcal vaccine
used in the U.S. military may elicit this type of cross-reactive
antibody, and such an antibody may be responsible for the
observed lack of increase in group B serotype outbreaks in the
U.S. military (5). The epitope bound by HmenB5 must include
the PSA because this MAb binds to the CHP-134 cell line and
to purified E. coli K1 PS. Interestingly, the mice carrying the
autoreactive hybridomas in their peritoneum did not show any
obvious neurological symptoms, consistent with previous ob-
servations of patients with a high level of anti-NCAM antibod-
ies due to myelomas or meningococcal infections (25).
In addition to the autoreactive antibodies, however, we also
obtained many MAbs recognizing a bacterium-specific epi-
tope(s). The bacterium-specific hybridomas bound to the
E. coli strain EV36. This finding indicates that an unrelated
(K-12) strain of E. coli can gain the bacterium-specific epitope
with the transfer of the gene only for the capsular PS of E. coli
K1. Also, the bacterium-specific epitope was present on the
purified E. coli K1 PS. These findings strongly support the idea
that the bacterium-specific epitope is the capsular PS or a
structure invariantly associated with the capsular PS. An ex-
ample of the invariably associated molecule is a lipid tail, which
is used to anchor the capsular PS to the membrane and which
is invariably found for the capsular PS of both E. coli and
NMGB (4, 14). Also, PS-lipid binds to the ELISA plates much
better than does pure PS (C. Frasch, personal communica-
tion). Thus, antibodies to PS-lipid would be efficiently detected
by the ELISA even though PS-lipid is only a minor contami-
FIG. 3. The amount of bacteriophage bound (y axis) to the micro-
wells coated with different MAbs versus various dilutions of phage
clones (x axis). Dilution (x axis) indicates fold dilutions, and the optical
density (y axis) is expressed in milli-absorbance units. PhaB3L1 (filled
circles), PhaB3C1 (open circles), and Pha-CNTL (inverted open tri-
angles) were tested with HmenB3-coated microwells. PhaB1L1 (filled
squares) was tested with HmenB1-coated microwells.
FIG. 4. (A) The amount of bacteriophage bound (y axis) to the microwells coated with different MAbs versus various concentrations of E. coli
K1 PS in solution (x axis). The optical density (y axis) was expressed in milli-absorbance units. The concentration of phage used for the experiment
was 1010 PFU/ml. PhaB3L1 (filled circles) and PhaB3C1 (open circles) were tested with HmenB3-coated microwells. PhaB1L1 (filled squares) was
tested with HmenB1-coated microwells. (B) Cross-reactive binding of the phage clones to microwells (y axis) versus the dilution of the phage stocks
(x axis). Dilution (x axis) indicates fold dilutions, and the optical density (y axis) is expressed in milli-absorbance units. Individual curves indicate
the binding of PhaB3L1 to HmenB3-coated microwells (filled circles), PhaB3L1 to HmenB1-coated microwells (open circles), PhaB1L1 to
HmenB1-coated microwells (filled squares), and PhaB1L1 to HmenB3-coated microwells (open squares).
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nant of the purified preparation of PS. The epitope is not likely
a protein because the preparation of purified E. coli K1 PS has
very little protein contamination (W. Vann, personal commu-
nication) and any such protein would have to be conserved
among widely different bacteria (E. coli versus N. meningitidis).
We are currently investigating the nature of the bacterium-
specific epitope further using EV36 variants with mutations in
the synthesis or transport of the capsular PS. EV36 is non-
pathogenic, and its use greatly simplifies such epitope studies.
These bacterium-specific MAbs differed in their bactericidal
potencies. HmenB2 is extremely potent, but some MAbs are
not bactericidal at all. All our hybridomas produce IgM anti-
body, and a possible explanation is that some highly potent
antibodies (e.g., HmenB2) may be hexameric IgM. Hexameric
IgM has been found to fix complement better (28) and is more
frequent among antibodies produced by peritoneal B cells
(17), which are often associated with B1 B cells and anti-PS
antibodies (16). A more likely possibility is that functional
variability resides in the V region of antibodies. The V region
differences may result in differences in the avidity or in the
recognized epitopes. Two recent studies support the idea that
the specificity of the epitope can be critically important for
antibody function. Casadevall and his colleagues have found
two types of IgM anticryptococcal antibodies (22): one type
binds the fungus with a rim-type pattern and is protective,
whereas the other type binds it with a puffy-type pattern and
is not protective. Another example was shown by Fusco et
al., who described an antibody that, in the presence of com-
plement alone, can kill group B streptococcus, which is a
gram-positive bacterium and is normally resistant to comple-
ment-mediated bacteriolysis (13). To examine the possibilities
described above, additional work is in progress.
When the peptide mimotopes of NMGB PS were obtained
with the bacterium-specific MAbs, the heterogeneity of their
epitopes was readily shown by the mimotope sequences. The
mimotopes obtained with one hybridoma readily demonstrate
the sequence similarities, and the consensus sequences can be
easily identified in some cases. For instance, SHxxxAF is the
readily recognizable consensus sequence of HmenB3 mimo-
topes. Identical mimotope sequences are frequently found among
the phage clones independently derived from one selecting
MAb. For instance, the PhaB14L1 sequence is expressed in 5
of 22 independent clones selected with HmenB14. In contrast
to the mimotopes produced with one selecting antibody, mi-
motope peptides obtained with different selecting antibodies
were quite distinct. For example, amino acids A, F, and H
are common for mimotopes only from HmenB3 but amino
acids L, M, and Q are common for those from HmenB14. An
exception was observed for the phage clones obtained with
HmenB2 and HmenB3. The sequences of the mimotopes were
often identical, and additional studies (data not shown) found
them to have the identical V region sequences (and the two
hybridomas must have been obtained from two different B cells
sharing the clonal origin). This finding is different from those
of Granoff et al., who obtained identical mimotopes using
different selecting antibodies with different fine specificities of
binding (15). While the reason for this difference is unclear, our
study identifies a large number of independent mimotopes that
may bind the antigen binding region of the NMGB PS-specific
antibodies.
Our mimotope sequences are different from the sequences
of the six mimotopes of NMGB PS reported by Moe et al. (23).
For instance, R is prominent in their sequences but not in our
sequences. R is common among many PS mimotopes and may
mimic hydroxyl groups. Their sequences have cysteine, but
ours do not. In contrast, amino acids P and S were common for
the phage clones from all the hybridomas. An unusual se-
quence is one in PhaB13L11 which has five P’s in succession
and likely forms a helix like NMGB PS. We believe, however,
that the helices are different since polyproline forms a collag-
en-like helix with a 9-Å pitch whereas NMGB PSA most likely
forms a helix with a 5.5-Å pitch (6). Another interesting phage
is PhaB13L4, which has a WSY sequence. The W/YXY se-
quence motif has been found in the peptide mimics of several
PS (31) including group C PS of N. meningitidis, another PSA
with an a(2-9) linkage group (33). No other obvious similari-
ties have been observed when our sequences were compared
with mimotopes of other PS molecules.
The recent identification of new vaccine candidate mole-
TABLE 4. Peptide mimotope sequences of clones of four MAbs
MAb Phagea Peptide sequenceb No. of clonesc
HmenB1 PhaB1L1 DHQRFFV 5/6
PhaB1L2 AHQASFV 1/6
HmenB3 PhaB3L1 SHVPNAF 23/37
PhaB3L2 SHAPNAF 6/37
PhaB3L3 SHVPDAF 4/37
PhaB3L4 SHVHNAF 2/37
PhaB3L5 SHAPSAF 1/37
PhaB3L6 SHVPHAF 1/37
PhaB3C1 (C) TGPGSWF (C) 6/10
PhaB3C2 (C) TSPGPWF (C) 2/10
PhaB3C3 (C) TAPGAWF (C) 1/10
PhaB3C4 (C) TTPGPWF (C) 1/10
HmenB13 PhaB13L1 VVSTGSH 5/17
PhaB13L2 IPMKGHW 1/17
PhaB13L3 LPMKYQA 1/17
PhaB13L4 HWGMWSY 1/17
PhaB13L5 ALSSDPH 1/17
PhaB13L6 DPRLSAL 1/17
PhaB13L7 KPSTLML 1/17
PhaB13L8 YHWYTSP 1/17
PhaB13L9 LFMPATP 1/17
PhaB13L10 ALLPWTD 1/17
PhaB13L11 SPPPPPI 1/17
PhaB13L12 SHAPYTH 1/17
PhaB13L13 NQDVPLF 1/17
HmenB14 PhaB14L1 MELQTRS 5/22
PhaB14L2 LPMKYQA 5/22
PhaB14L3 NTLQPSP 2/22
PhaB14L4 YMTPFSP 2/22
PhaB14L5 LHAQSRS 1/22
PhaB14L6 YHLQPTP 1/22
PhaB14L7 HFMEPVN 1/22
PhaB14L8 LSTPSLL 1/22
PhaB14L9 ITAARLP 1/22
PhaB14L10 SIDNPLP 1/22
PhaB14L11 SIITGYL 1/22
PhaB14L12 AYSMLGH 1/22
a Phage clones with linear random peptides (L).
b Sequences of clones from heptapeptide insert or circular random peptide (C)
phage library after third biopanning by HmenB1, HmenB3, HmenB13, and
HmenB14.
c Number of identical peptide sequences/total number of sequences.
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cules (26) has opened a new approach to making a vaccine
against NMGB. However, these molecules have not been ex-
tensively studied so far, and the prospects for their becoming a
successful vaccine are still unclear. In contrast, the capsular PS
of NMGB has been extremely well studied, and the antibodies
to NMGB PS have been shown to be effective against all strains
of NMGB. There is also an increasing body of literature show-
ing that mimotopes can serologically mimic carbohydrate epi-
topes and elicit antibodies to a variety of PS antigens including
group C meningococcal PS (33), cryptococcal capsular PS
(D. O. Beenhouwer, P. Valadon, R. May, S. L. Morrison, and
M. D. Scharff, FASEB J. 14:A947, 2000), or carbohydrate epi-
topes of human immunodeficiency virus type 1 or respiratory
syncytial virus (7) and other PS (2, 31). Thus, we believe that
bacterium-specific anti-NMGB PS antibody can be induced
with the mimotopes. We are currently investigating the immu-
nogenicity of additional mimotopes and the interaction be-
tween the mimotope peptide and the antibody in detail.
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